Abstract |
The prevention of vancomycin-resistant Enterococcus (VRE) colonization and infection continues to be a high priority for clinicians. An oral antimicrobial agent that reduces or eliminates VRE gastrointestinal colonization could be useful for preventing VRE infection in selected patients. Ramoplanin, a glycolipodepsipeptide, is the first in a new class of antimicrobials. It has excellent in vitro activity against vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. It is orally administered, and not absorbed systemically. In clinical trials, VRE gastrointestinal colonization was reduced to undetectable levels in 80-90% of patients during receipt of ramoplanin. A randomized, double-blinded, placebo-controlled multicentre study is currently being conducted to determine whether ramoplanin will prevent VRE bloodstream infection in oncology patients who are neutropenic due to treatment for a haematological malignancy or a bone marrow/stem cell transplant.
|
Authors | Marisa A Montecalvo |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 51 Suppl 3
Pg. iii31-5
(Jun 2003)
ISSN: 0305-7453 [Print] England |
PMID | 12801940
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Depsipeptides
- Peptides, Cyclic
- ramoplanin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Clinical Trials as Topic
- Depsipeptides
- Enterococcus
(drug effects, genetics, isolation & purification)
- Gram-Positive Bacterial Infections
(prevention & control)
- Humans
- Neoplasms
(complications)
- Opportunistic Infections
(prevention & control)
- Peptides, Cyclic
(therapeutic use)
- Treatment Outcome
- Vancomycin Resistance
(genetics)
|